CytomX Therapeutics, Inc.

How big is CytomX Therapeutics, Inc.?

As of Jun 18, CytomX Therapeutics, Inc. has a market capitalization of 374.96 million, with net sales of 147.55 million and a net profit of 41.61 million over the last four quarters. The balance sheet indicates shareholder's funds of -0.46 million and total assets of 122.64 million.

As of Jun 18, CytomX Therapeutics, Inc. has a market capitalization of 374.96 million, categorizing it as a Micro Cap company.<BR><BR>As of the latest four quarters, the company reported net sales of 147.55 million and a net profit of 41.61 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of -0.46 million and total assets of 122.64 million.

What does CytomX Therapeutics, Inc. do?

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, with a market cap of approximately USD 375 million. As of March 2025, it reported net sales of USD 51 million and a net profit of USD 24 million.

Overview:<BR>CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company operating in the Pharmaceuticals & Biotechnology industry with a market cap of USD 374.96 million.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 51 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 24 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 374.96 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 10.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.98 <BR>Return on Equity: 166.09% <BR>Price to Book: 14.97<BR><BR>Contact Details:<BR>Address: 151 Oyster Point Blvd Ste 400, SOUTH SAN FRANCISCO CA 94080-1910 <BR>Tel: 1 650 5153185 <BR>Fax: 1 650 3510353 <BR>Website: http://cytomx.com/

Should I buy, sell or hold CytomX Therapeutics, Inc.?

Who are in the management team of CytomX Therapeutics, Inc.?

As of March 2022, the management team of CytomX Therapeutics, Inc. is led by Dr. Sean McCarthy as Chairman, President, and CEO, with Mr. Matthew Young as Lead Independent Director and additional independent directors including Dr. Mani Mohindru, Dr. Charles Fuchs, Ms. Halley Gilbert, and Mr. Frederick Gluck.

As of March 2022, the management team of CytomX Therapeutics, Inc. includes Dr. Sean McCarthy, who serves as the Chairman of the Board, President, and Chief Executive Officer. Other members of the board include Mr. Matthew Young as the Lead Independent Director, Dr. Mani Mohindru as a Director, Dr. Charles Fuchs as an Independent Director, Ms. Halley Gilbert as an Independent Director, and Mr. Frederick Gluck as an Independent Director.

Is CytomX Therapeutics, Inc. overvalued or undervalued?

As of September 3, 2025, CytomX Therapeutics, Inc. is considered very attractive in valuation due to its low P/E ratio of 10, favorable PEG ratio of 0.14, and strong EV to EBITDA ratio of 9.07, indicating significant growth potential despite a challenging long-term performance.

As of 3 September 2025, the valuation grade for CytomX Therapeutics, Inc. has moved from attractive to very attractive, indicating a significant improvement in its valuation outlook. The company appears to be undervalued, particularly given its P/E ratio of 10, which is favorable compared to the industry average, and a PEG ratio of 0.14, suggesting strong growth potential relative to its price. Additionally, the EV to EBITDA ratio stands at 9.07, further supporting the undervaluation thesis.<BR><BR>In comparison to its peers, CytomX Therapeutics shows a much lower P/E ratio than Chimerix, Inc. at -8.6897 and a more favorable EV to EBITDA than Aquestive Therapeutics, Inc. at -12.8252, highlighting its relative strength in valuation metrics. While the stock has experienced a YTD return of 98.06% compared to the S&P 500's 12.22%, it has struggled in the longer term, with a 5Y return of -72.43% versus the S&P 500's 96.61%. This contrast in performance underscores the potential for recovery and growth in the coming periods.

Is CytomX Therapeutics, Inc. technically bullish or bearish?

As of July 24, 2025, CytomX Therapeutics, Inc. shows a mildly bullish trend, supported by daily moving averages, despite mixed signals from weekly MACD and Bollinger Bands, while year-to-date performance is strong at 98.06%, though it has underperformed over the past 5 and 10 years.

As of 24 July 2025, the technical trend for CytomX Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while the weekly MACD and Bollinger Bands show mildly bearish signals. The monthly MACD is mildly bullish, but the RSI indicates a bearish trend. The stock has performed well year-to-date with a return of 98.06% compared to the S&P 500's 12.22%, but it has underperformed over longer periods, particularly in the 5-year and 10-year comparisons.